CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient

Bulletin Express05-26

CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient enrollment.

The trial, formally launched after National Medical Products Administration approval in January 2026, will assess safety and immunogenicity in participants aged six weeks and older. PCV24 targets 24 circulating pneumococcal serotypes and leverages covalent conjugation of polysaccharide antigens to dual protein carriers (CRM197 and tetanus toxoid).

PCV24 expands CANSINOBIO’s pneumococcal portfolio, following the June 2025 Chinese market approval of its 13-valent product, iPneucia. No 24-valent pneumococcal conjugate vaccine is currently available worldwide, positioning PCV24 as a potential first-in-class entrant.

The company cautions shareholders and prospective investors to exercise prudent judgment when trading its shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149227006?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 08:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149227006","market":"us","top_or_hot":-1,"title":"CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient","media":"Bulletin Express","content":"<p>CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient enrollment.</p>\n<p>The trial, formally launched after National Medical Products Administration approval in January 2026, will assess safety and immunogenicity in participants aged six weeks and older. PCV24 targets 24 circulating pneumococcal serotypes and leverages covalent conjugation of polysaccharide antigens to dual protein carriers (CRM197 and tetanus toxoid).</p>\n<p>PCV24 expands CANSINOBIO’s pneumococcal portfolio, following the June 2025 Chinese market approval of its 13-valent product, iPneucia. No 24-valent pneumococcal conjugate vaccine is currently available worldwide, positioning PCV24 as a potential first-in-class entrant.</p>\n<p>The company cautions shareholders and prospective investors to exercise prudent judgment when trading its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO Initiates Phase I/II Trial of 24-Valent Pneumococcal Conjugate Vaccine PCV24, Enrolls First Patient\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-26 08:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient enrollment.</p>\n<p>The trial, formally launched after National Medical Products Administration approval in January 2026, will assess safety and immunogenicity in participants aged six weeks and older. PCV24 targets 24 circulating pneumococcal serotypes and leverages covalent conjugation of polysaccharide antigens to dual protein carriers (CRM197 and tetanus toxoid).</p>\n<p>PCV24 expands CANSINOBIO’s pneumococcal portfolio, following the June 2025 Chinese market approval of its 13-valent product, iPneucia. No 24-valent pneumococcal conjugate vaccine is currently available worldwide, positioning PCV24 as a potential first-in-class entrant.</p>\n<p>The company cautions shareholders and prospective investors to exercise prudent judgment when trading its shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1149227006","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149227006","pubTimestamp":1779755154,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"康希诺生物启动24价肺炎球菌结合疫苗PCV24 I/II期试验，入组首例患者","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CanSino Biologics Inc. (CANSINOBIO) has commenced a Phase I/II clinical study for its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT), PCV24, and recorded the first patient enrollment.\nThe trial, formally launched after National Medical Products Administration approval in January 2026, will assess safety and immunogenicity in participants aged six weeks and older. PCV24 targets 24 circulating pneumococcal serotypes and leverages covalent conjugation of polysaccharide antigens to dual protein carriers (CRM197 and tetanus toxoid).\nPCV24 expands CANSINOBIO’s pneumococcal portfolio, following the June 2025 Chinese market approval of its 13-valent product, iPneucia. No 24-valent pneumococcal conjugate vaccine is currently available worldwide, positioning PCV24 as a potential first-in-class entrant.\nThe company cautions shareholders and prospective investors to exercise prudent judgment when trading its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149227006","isCrawlerRequest":true}